• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

肝细胞癌免疫相关预后标志物的鉴定与验证

Identification and Validation of an Immune-related Prognostic Signature for Hepatocellular Carcinoma.

作者信息

Xia Xinxin, Tang Ping, Liu Hui, Li Yuejun

机构信息

Department of Traditional Chinese Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.

Department of Oncology, The Third Affiliated Hospital of Hunan University of Chinese Medicine, Zhuzhou, Hunan, China.

出版信息

J Clin Transl Hepatol. 2021 Dec 28;9(6):798-808. doi: 10.14218/JCTH.2021.00017. Epub 2021 Aug 17.

DOI:10.14218/JCTH.2021.00017
PMID:34966643
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8666365/
Abstract

BACKGROUND AND AIMS

The immune system plays vital roles in hepatocellular carcinoma (HCC) initiation and progression. The present study aimed to construct an immune-gene related prognostic signature (IRPS) for predicting the prognosis of HCC patients.

METHODS

Gene expression data were retrieved from The Cancer Genome Atlas database. The IRPS was established via least absolute shrinkage and selection operator (LASSO) and multivariate Cox regression analysis. The prognostic values of the IRPS were further validated using the International Cancer Genome Consortium (ICGC) dataset.

RESULTS

A total of 62 genes were identified as candidate immune-related prognostic genes. According to the results of Lasso and multivariate Cox regression analysis, we established an IRPS and confirmed its stability and reliability in the ICGC dataset. The IRPS was significantly associated with advanced clinicopathological characteristics. Both Cox regression analyses revealed that the IRPS could be independent risk factors influencing prognosis of HCC patients. The relationships between the IRPS and infiltration of immune cells demonstrated that the IRPS was associated with immune cell infiltration. Furthermore, a nomogram was constructed to estimate the survival probability of HCC patients.

CONCLUSIONS

The IRPS was effective for predicting prognosis of HCC patients, which might serve as novel prognostic and therapeutic biomarkers for HCC.

摘要

背景与目的

免疫系统在肝细胞癌（HCC）的发生和发展中起着至关重要的作用。本研究旨在构建一种免疫基因相关的预后特征（IRPS），用于预测HCC患者的预后。

方法

从癌症基因组图谱数据库中检索基因表达数据。通过最小绝对收缩和选择算子（LASSO）和多变量Cox回归分析建立IRPS。使用国际癌症基因组联盟（ICGC）数据集进一步验证IRPS的预后价值。

结果

共鉴定出62个基因作为候选免疫相关预后基因。根据Lasso和多变量Cox回归分析结果，我们建立了IRPS，并在ICGC数据集中证实了其稳定性和可靠性。IRPS与晚期临床病理特征显著相关。两项Cox回归分析均显示，IRPS可能是影响HCC患者预后的独立危险因素。IRPS与免疫细胞浸润之间的关系表明，IRPS与免疫细胞浸润有关。此外，构建了一个列线图来估计HCC患者的生存概率。

结论

IRPS对预测HCC患者的预后有效，可能作为HCC新的预后和治疗生物标志物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf2d/8666365/a1e508c3042b/JCTH-9-798-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf2d/8666365/4315b3b4981f/JCTH-9-798-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf2d/8666365/912326a3f56a/JCTH-9-798-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf2d/8666365/06d1aea00c56/JCTH-9-798-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf2d/8666365/79657c954076/JCTH-9-798-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf2d/8666365/ac298a55a898/JCTH-9-798-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf2d/8666365/48eda8cd9920/JCTH-9-798-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf2d/8666365/9d583fc24104/JCTH-9-798-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf2d/8666365/a1e508c3042b/JCTH-9-798-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf2d/8666365/4315b3b4981f/JCTH-9-798-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf2d/8666365/912326a3f56a/JCTH-9-798-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf2d/8666365/06d1aea00c56/JCTH-9-798-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf2d/8666365/79657c954076/JCTH-9-798-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf2d/8666365/ac298a55a898/JCTH-9-798-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf2d/8666365/48eda8cd9920/JCTH-9-798-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf2d/8666365/9d583fc24104/JCTH-9-798-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf2d/8666365/a1e508c3042b/JCTH-9-798-g008.jpg

相似文献

1
Identification and Validation of an Immune-related Prognostic Signature for Hepatocellular Carcinoma.肝细胞癌免疫相关预后标志物的鉴定与验证
J Clin Transl Hepatol. 2021 Dec 28;9(6):798-808. doi: 10.14218/JCTH.2021.00017. Epub 2021 Aug 17.
2
Four-gene signature predicting overall survival and immune infiltration in hepatocellular carcinoma by bioinformatics analysis with RT‒qPCR validation.基于生物信息学分析和 RT-qPCR 验证的四基因signature 预测肝细胞癌的总生存和免疫浸润。
BMC Cancer. 2022 Jul 30;22(1):830. doi: 10.1186/s12885-022-09934-1.
3
Identification and Validation of a Novel Six-Gene Expression Signature for Predicting Hepatocellular Carcinoma Prognosis.鉴定和验证一种新型的六基因表达谱用于预测肝细胞癌预后。
Front Immunol. 2021 Dec 1;12:723271. doi: 10.3389/fimmu.2021.723271. eCollection 2021.
4
Development and validation of a novel immune-related prognostic model in hepatocellular carcinoma.一种新型肝细胞癌免疫相关预后模型的开发与验证
J Transl Med. 2020 Feb 11;18(1):67. doi: 10.1186/s12967-020-02255-6.
5
A Novel Metabolism-Related Signature as a Candidate Prognostic Biomarker for Hepatocellular Carcinoma.一种新型代谢相关特征作为肝细胞癌潜在预后生物标志物
J Hepatocell Carcinoma. 2021 Mar 16;8:119-132. doi: 10.2147/JHC.S294108. eCollection 2021.
6
An immune infiltration-related long non-coding RNAs signature predicts prognosis for hepatocellular carcinoma.一种与免疫浸润相关的长链非编码RNA特征可预测肝细胞癌的预后。
Front Genet. 2022 Dec 8;13:1029576. doi: 10.3389/fgene.2022.1029576. eCollection 2022.
7
Identification of a Liver Progenitor Cell-Related Genes Signature Predicting Overall Survival for Hepatocellular Carcinoma.鉴定与肝祖细胞相关的基因特征，预测肝细胞癌的总生存期。
Technol Cancer Res Treat. 2021 Jan-Dec;20:15330338211041425. doi: 10.1177/15330338211041425.
8
Development and validation of a robust epithelial-mesenchymal transition (EMT)-related prognostic signature for hepatocellular carcinoma.一种用于肝细胞癌的稳健的上皮-间质转化（EMT）相关预后标志物的开发与验证
Clin Res Hepatol Gastroenterol. 2021 Sep;45(5):101587. doi: 10.1016/j.clinre.2020.101587. Epub 2021 Mar 1.
9
Identification of a Novel Immune Landscape Signature for Predicting Prognosis and Response of Endometrial Carcinoma to Immunotherapy and Chemotherapy.一种用于预测子宫内膜癌免疫治疗和化疗预后及反应的新型免疫景观特征的鉴定
Front Cell Dev Biol. 2021 Jul 23;9:671736. doi: 10.3389/fcell.2021.671736. eCollection 2021.
10
Development and validation of an eight-gene signature based predictive model to evaluate the prognosis of hepatocellular carcinoma patients: a bioinformatic study.基于八基因特征的预测模型用于评估肝细胞癌患者预后的开发与验证：一项生物信息学研究
Ann Transl Med. 2022 May;10(9):524. doi: 10.21037/atm-22-1934.

引用本文的文献

1
Identification of immune-related genes and patient selection for hepatocellular carcinoma immunotherapy.肝细胞癌免疫治疗免疫相关基因的鉴定及患者选择
Transl Cancer Res. 2023 May 31;12(5):1210-1231. doi: 10.21037/tcr-22-2304. Epub 2023 Apr 13.
2
Comprehensive analysis of an autophagy-related prognostic model for predicting survival based on TCGA and ICGC database in hepatocellular carcinoma patients.基于TCGA和ICGC数据库对肝细胞癌患者进行生存预测的自噬相关预后模型的综合分析。
J Gastrointest Oncol. 2022 Dec;13(6):3154-3168. doi: 10.21037/jgo-22-1130.
3
Noncoding RNAs-mediated overexpression of KIF14 is associated with tumor immune infiltration and unfavorable prognosis in lung adenocarcinoma.

本文引用的文献

1
A Prognostic Model of 15 Immune-Related Gene Pairs Associated With Tumor Mutation Burden for Hepatocellular Carcinoma.一种与肝细胞癌肿瘤突变负荷相关的15个免疫相关基因对的预后模型。
Front Mol Biosci. 2020 Nov 13;7:581354. doi: 10.3389/fmolb.2020.581354. eCollection 2020.
2
Impact of Immune Response on Outcomes in Hepatocellular Carcinoma: Association With Vascular Formation.免疫反应对肝细胞癌结局的影响：与血管形成的关联。
Hepatology. 2020 Dec;72(6):1987-1999. doi: 10.1002/hep.31206. Epub 2020 Oct 20.
3
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO.
非编码 RNA 介导的 KIF14 过表达与肺腺癌的肿瘤免疫浸润和不良预后相关。
Aging (Albany NY). 2022 Oct 11;14(19):8013-8031. doi: 10.18632/aging.204332.
泛亚地区适应性 ESMO 临床实践指南：管理中晚期/复发肝细胞癌患者 - TOS-ESMO 倡议得到 CSCO、ISMPO、JSMO、KSMO、MOS 和 SSO 的支持。
Ann Oncol. 2020 Mar;31(3):334-351. doi: 10.1016/j.annonc.2019.12.001. Epub 2019 Dec 20.
4
Molecular therapies for HCC: Looking outside the box.肝细胞癌的分子疗法：跳出框框思考。
J Hepatol. 2020 Feb;72(2):342-352. doi: 10.1016/j.jhep.2019.09.010.
5
Immunotherapy for hepatocellular carcinoma.肝细胞癌的免疫治疗。
Cancer Lett. 2020 Feb 1;470:8-17. doi: 10.1016/j.canlet.2019.12.002. Epub 2019 Dec 4.
6
Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma.晚期肝细胞癌的分子靶向和免疫检查点治疗。
J Exp Clin Cancer Res. 2019 Nov 4;38(1):447. doi: 10.1186/s13046-019-1412-8.
7
The immunobiology of hepatocellular carcinoma in humans and mice: Basic concepts and therapeutic implications.人类和小鼠肝细胞癌的免疫生物学：基本概念和治疗意义。
J Hepatol. 2020 Jan;72(1):167-182. doi: 10.1016/j.jhep.2019.08.014. Epub 2019 Aug 23.
8
A global view of hepatocellular carcinoma: trends, risk, prevention and management.全球视角下的肝细胞癌：趋势、风险、预防与管理。
Nat Rev Gastroenterol Hepatol. 2019 Oct;16(10):589-604. doi: 10.1038/s41575-019-0186-y. Epub 2019 Aug 22.
9
An Immune Gene Expression Signature Associated With Development of Human Hepatocellular Carcinoma Identifies Mice That Respond to Chemopreventive Agents.与人类肝细胞癌发展相关的免疫基因表达谱可识别对化学预防剂有反应的小鼠。
Gastroenterology. 2019 Nov;157(5):1383-1397.e11. doi: 10.1053/j.gastro.2019.07.028. Epub 2019 Jul 22.
10
Prediction of Overall Survival in Gastric Cancer Using a Nine-lncRNA.基于九个长链非编码 RNA 预测胃癌患者的总生存期
DNA Cell Biol. 2019 Sep;38(9):1005-1012. doi: 10.1089/dna.2019.4832. Epub 2019 Jul 23.